Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment

Peter Joseph Jongen¹
Evert Sanders²
Cees Zwanikken³
Jan Koeman⁴
Leo H Visser⁵
Petra Koopmans⁶
Dirk Lehnick⁷
OPTIVIT study group

¹MS4 Research Institute, Nijmegen, ²Amphia Ziekenhuis, Breda, ³Maxima Medisch Centrum, Eindhoven, ⁴Admiraal de Ruyter Ziekenhuis, Vlissingen, ⁵St Elisabeth Ziekenhuis, Tilburg, ⁶Signidat, Groningen, The Netherlands; ⁷Nuvisan GmbH, Neu-Ulm, Germany

Background: The participation of neurologists and patients in studies on the effectiveness and safety of newly authorized drugs in multiple sclerosis (MS) is insufficient. Monthly online self-assessments using patient-reported outcomes may help in short-term monitoring of neurological changes and side effects.

Objective: Investigate in relapsing-remitting (RR) MS patients the adherence to monthly online self-assessments after the start of disease modifying treatment.

Methods: Observational study in 39 neurological departments in The Netherlands. Patients starting glatiramer acetate treatment were instructed to complete online the Modified Fatigue Impact Scale 5-item version and the 8-item Leeds Multiple Sclerosis Quality of Life scale every month during 1 year (T0 to T12).

Results: Sixty-three investigators included 163 analyzable patients. At T3, 148 (90.8%) patients had completed all questionnaires; at T6, 142 (87.1%); at T9, 133 (81.6%); and at T12, 123 (75.5%). Eight (4.9%) patients did not complete any questionnaire. Median values for inter-assessment intervals ranged from 32 to 34 days (first quartile [Q1] 30 days, third quartile [Q3] 41 days), and the final assessment was at 417 days (median: Q1 385 days, Q3 480 days). Forty-three (26.3%) patients completed the questionnaires at all time points (completion adherent) with their final assessment within 30 days after the scheduled T12 (interval adherent). Eighty (49.1%) patients were completion adherent, but not interval adherent. Forty (24.5%) patients were not completion adherent, as they discontinued assessments prematurely. Men were more interval adherent than women (47.5% vs 20.0%; \( P = 0.001 \)).

Conclusion: The observation that three out of four (75.5%) RRMS patients completed two short questionnaires at all monthly time points during 1 year after the start of disease modifying treatment suggests that intensive online monitoring in this patient group is feasible. As only one in five (19.6%) patients adhered to the time intervals between self-assessments, measures are needed that improve the timely completion of questionnaires.

Keywords: effectiveness, glatiramer acetate, fatigue, health-related quality of life, MFIS-5, LMSQoL

Introduction

In recent years, new drugs have become available for the treatment of relapsing–remitting (RR) multiple sclerosis (MS) and MS-related walking disability.¹⁴ After authorization the effectiveness of these drugs has to be evaluated in large numbers of patients, treated in various settings of daily practice. However, most effectiveness studies in MS involve only a small number of hospitals with an underrepresentation of
general neurological practices, as busy schedules and limited resources make it difficult for neurologists to participate. In RRMS a clinical worsening in the first year of disease modifying drug (DMD) treatment predicts a worse long-term disability.\(^5\) To be able to consider treatment alternatives in a timely fashion it is therefore necessary to closely monitor clinical disease activity. Since the detection of relapses is patient-driven, a relapse might not be a sufficiently reliable sign of clinical disease activity. For, during DMD treatment, as well as in an advanced stage of RRMS, relapses may be atypical by developing gradually and therefore be noticed less readily by patients. Moreover, a relapse-induced increase in disability and the degree of recovery are relevant aspects as well that need to be quantified when assessing disease activity. In clinical trials relapse-related disability is measured by the Expanded Disability Status Scale (EDSS).\(^1\) However, this measure is time consuming, fails to adequately assess fatigue and cognitive impairment, and does not quantify the disease burden from the patient’s perspective. Patient-reported outcomes (PROs) reflecting various aspects of disability may counterbalance these shortcomings.\(^7\) Interestingly, the second-line DMDs not only prevent relapses but may also lead to clinical improvements, that should be adequately documented for treatment evaluation. As to safety monitoring of DMDs, pre-defined frequent assessments may detect safety issues more comprehensively and earlier than patient-initiated reporting. Finally, from a methodological viewpoint it can be argued that repeated measurements provide more reliable information on disability and side effects than single pre- and posttreatment assessments.

Given these considerations, we imagined that the requirements for optimal monitoring of disease activity and safety after the start of a DMD treatment in RRMS might not be fully met by regular outpatient visits using doctor-centered measures and that more frequent assessments using PROs could have an added value.

Online questionnaires and diaries for self-assessment can be completed at home at convenient time points; errors and missing data are minimized by automated checks of completeness and consistency; electronic data capture prevents transmission errors; and scores are calculated automatically.\(^8\)-\(^10\) As the online use of PROs does not depend on out-patient visits, monitoring may be more intensive. Moreover, online use of PROs could provide information that complements or substitutes doctor-reported data, rendering monitoring less burdensome for neurologists.\(^11\)

In view of the above, we investigated whether patients with RRMS would adhere to a monthly online self-assessment schedule to monitor aspects of effectiveness after the start of disease modifying treatment. The choice of the variables was based on the availability of short validated questionnaires assessing the past month, and on their potential clinical relevance. So we chose fatigue – a frequent and disabling symptom in MS - and health-related quality of life – an overall measure of well-being from a patient’s perspective.

**Methods**

**Study design and procedures**

This was a prospective, observational, multicenter study in which 54 neurologists and nine MS nurses participated from 39 neurological outpatient departments in The Netherlands. The information on the study was given by the neurologist or the nurse. Patients who agreed to participate signed an informed consent form. Because of the observational design of the study, a review by an ethical committee was not required, as the study did not meet the criteria stated in the Dutch Medical Research Involving Human Subjects Act of 1999.\(^12\) The study was carried out in compliance with the Declaration of Helsinki.

After having received a personal code, patients logged on to the study website to choose a username and password. To protect the personal data from unauthorized access, various mechanisms were used to ensure compliance with European Union regulations concerning online medical data. Patients were instructed to visit the website http://www.gezondheidsmeter.nl at the start of treatment, or as soon as possible in case they had already started treatment, and at monthly intervals thereafter during a period of 12 months (T1 to T12), in order to complete two short questionnaires: the Modified Fatigue Impact Scale 5-item version (MFIS-5) and the Leeds Multiple Sclerosis Quality of Life (LMSQoL) scale. The MFIS-5 is a validated, short, 5-item questionnaire examining a patient’s perception of fatigue over the past month.\(^13,14\) The LMSQoL is a validated, short questionnaire consisting of eight questions, examining MS-related aspects of health-related quality of life over the past month.\(^15,16\)

Patients were sent an email informing them of the fact that the questionnaires were available online for completion. Patients who had not completed the questionnaires within 1 week were sent a reminder email. Those who had not completed the questionnaires within 1 week after this latter email were given a reminder phone call by the study help desk.

The questionnaires ran on the Curavista Health platform, a fully operational online business application for patient–health care provider communication that was already being used in various settings. The responses
were automatically captured. The data collection started October 1, 2004 (first patient in), recruitment stopped July 31, 2007 (last patient in), and the closure of the database was December 31, 2008 (last patient out). The items of the two questionnaires were fixed, without randomization or alternation. Adaptive questioning was not used. The MFIS-5 consisted of five items that were presented on one page (Figure 1), and the LMSQoL consisted of eight items presented on another page. Consistency and completeness checks were done before a questionnaire was submitted (Oracle Database [Oracle, Redwood Shores, CA, USA] with JAVA scripting). The patients saw an overview of all questions and answers before submitting and could change the answers before submitting. After submission changes were no longer possible. Users were registered by their doctors, using date of birth and email address. Via graphs, patients were given online feedback on their scores and the respective changes over time (Figure 2). To this end, the maximum scores of both scales were transformed to 100%, and the fatigue score was inversed to represent “fitness.”

Patients
Inclusion criteria were: (1) diagnosis of RRMS; (2) at least 18 years of age; (3) relapse- and steroid-free for at least 30 days; and (4) willing and able to complete online questionnaires. Exclusion criteria were: (1) hypersensitivity to glatiramer acetate or mannitol; (2) pregnancy or lactation; (3) glatiramer acetate treatment for more than 3 months; and (4) previous glatiramer acetate treatment. One-hundred-seventy-six patients were included. In 13 patients the inclusion was a protocol violation since the disease course was not RR or was unknown (n = 9), or the patients had started treatment more than 3 months before study entry (n = 4).

The data analysis set consisted of 163 patients. Mean value for age at baseline was 40.9 years (95% confidence interval [CI] 39.3–42.4 years), for disease duration was 5.2 years (95% CI 4.4–6.0 years), and for EDSS score was 2.8 (95% CI 2.5–3.1).

Outcome measures
Study outcome was the adherence to the monthly self-assessment schedule. Measures for adherence were (1) the percentages of patients that had completed all questionnaires at the time points T3, T6, T9 and T12, and (2) the intervals between two consecutive self-assessments and between the baseline and T12 assessment.

Patients were classified as completion adherent if they had completed both questionnaires at all time points.

Figure 1 Screenshot of the five items of the MFIS-5 questionnaire. Copyright © 2012, Curavista bv, Geertruidenberg, Netherlands. Reprinted with permission.

Notes: Questions: (1) Due to my fatigue I have been less alert. (2) Due to my fatigue I have been limited in my ability to do things away from home. (3) Due to my fatigue I have had trouble maintaining physical efforts for long periods. (4) Due to my fatigue I have been less able to complete tasks that require physical effort. (5) Due to my fatigue I have had trouble concentrating. Possible answers: never, seldom, sometimes, often, almost always.

Abbreviation: MFIS-5, Modified Fatigue Impact Scale 5-item version.
Completion-adherent patients who had completed the study within 30 days after the scheduled T12 date were classified as interval adherent.

**Statistical analysis**

The numbers and percentages of patients who completed the questionnaires at the various time points were calculated, as well as the intervals (days) between two consecutive self-assessments and between the baseline and T12 assessment.

In order to test for significance, for categorical variables we used the Chi-square test (Pearson's Chi-square test) and, for ordinal variables, the Chi-square test for trend (linear-by-linear association). The difference in continuous variables between two groups was tested by means of the nonparametric Mann-Whitney U-test. We performed analyses of adherence by sex, age, and duration of disease (Chi-square test). For statistical analysis we used SAS (v 9.1.3; SAS Institute Inc, Cary, NC, USA) and SPSS (v 19 or higher; IBM Corporation, Armonk, NY, USA).

**Results**

**Completion of questionnaires**

Figure 3 presents the numbers and percentages of patients who completed the MFIS-5 and LMSQoL questionnaires at the consecutive time points. Eight (4.9%) of the 163 patients did not complete any questionnaire at any time point. In 155 (95.1%) patients the MFIS-5 and LMSQoL questionnaires were always completed in combination. Patients who stopped self-assessments had completed all questionnaires until stopping. At T3 148 patients, being 90.8% of all patients and 95.5% of the patients who had performed their baseline assessment, had completed all questionnaires. At T6 this number was 142 (87.1%, 91.6%), at T9 it was 133 (81.6%, 85.8%), and at T12 it was 123 (75.5%, 79.4%).

**Time intervals**

Intervals (days) between two consecutive self-assessments and between the baseline and final self-assessment (T12) are given in Table 1. Median values for intervals between two consecutive assessments ranged from 32 to 34 days. The median time between T0 and T12 was 417 days.

**Completion adherence and interval adherence**

One-hundred-twenty-three (75.5%) patients were completion adherent, whereas 40 (24.5%) were not completion adherent (premature discontinuation of self-assessments). Of the completion adherent patients, 43 (26.3% of the total group) were interval adherent and 80 (49.1% of the total group) patients were not interval adherent (final self-assessment later than 30 days after scheduled T12).

There was no difference between the completion adherence rate in men and in women (75.0% vs 77.5%; \( P = 0.75 \)). However, men were more often interval adherent than women (47.5% vs 20.0%; \( P = 0.001 \)). For age, disease duration, and pretreatment, there were no significant differences between adherent and nonadherent patients. The numbers of patient per center were too low to include centers in the analyses.
Discussion

In a prospective, observational, multicenter study we investigated the adherence to monthly online self-assessments in RRMS patients during 12 months after the start of disease modifying treatment. Adherence to the completion of two short questionnaires at all time points (completion adherence) and adherence to the scheduled monthly intervals (interval adherence) were evaluated. It was found that 75.5% of the patients were completion adherent, but only 19.6% were interval adherent. The intervals between two consecutive scheduled assessments were systematically exceeded by 2 to 4 days (median), leading to an extension of the 12-month study period by 1.7 months (median). One in four patients (26.3%) was both completion adherent and interval adherent. Almost half of the patients (49.1%) were completion adherent, but failed to comply with the predetermined monthly intervals. Interestingly, male patients were more likely to be interval adherent than women.

Post-authorization research is important to evaluate the effectiveness, side effects, and safety of newly authorized drugs in daily practice. Internet usage is well accepted by MS patients. Academic MS centers, national networks of MS centers, and patient communities have developed tools for patient-centered web-based research. Web-based studies can collect “real-world” information on the therapeutic use of drugs from the patient’s perspective using appropriate PROs. In patients who start a treatment, the intensive online monitoring of predefined outcomes may facilitate the collection of data on the short-term effects.

A major factor determining the practicability of intensive online monitoring is the adherence to the self-assessment schedule. Whether the completion and interval adherence rates in monthly assessments that we found in RRMS patients are adequate depends on the variable that is monitored, the psychometric characteristics of the PRO, and the goal of the monitoring. In MS, the potential applications of intensive online monitoring by self-assessments include the evaluation of the effectiveness of disease modifying treatments and the follow-up of the recovery from a relapse (disability, impact of disability, and quality of life questionnaires), the evaluation of the effectiveness of symptomatic treatments.

Table 1 Intervals (days) between two consecutive time points (T) of self-assessment and between baseline and final self-assessment

<table>
<thead>
<tr>
<th>Interval</th>
<th>N</th>
<th>Mean</th>
<th>SD</th>
<th>Q1</th>
<th>Median</th>
<th>Q3</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0–T1</td>
<td>155</td>
<td>39.1</td>
<td>16.4</td>
<td>31</td>
<td>33</td>
<td>37</td>
</tr>
<tr>
<td>T1–T2</td>
<td>152</td>
<td>36.4</td>
<td>12.7</td>
<td>30</td>
<td>32</td>
<td>37</td>
</tr>
<tr>
<td>T2–T3</td>
<td>148</td>
<td>37.4</td>
<td>13.4</td>
<td>30</td>
<td>32</td>
<td>37</td>
</tr>
<tr>
<td>T3–T4</td>
<td>148</td>
<td>36.7</td>
<td>13.3</td>
<td>30</td>
<td>32</td>
<td>37</td>
</tr>
<tr>
<td>T4–T5</td>
<td>146</td>
<td>38.7</td>
<td>22.8</td>
<td>31</td>
<td>33</td>
<td>37</td>
</tr>
<tr>
<td>T5–T6</td>
<td>142</td>
<td>36.4</td>
<td>11.9</td>
<td>30</td>
<td>32</td>
<td>36</td>
</tr>
<tr>
<td>T6–T7</td>
<td>140</td>
<td>37.1</td>
<td>13.8</td>
<td>30</td>
<td>32</td>
<td>37</td>
</tr>
<tr>
<td>T7–T8</td>
<td>136</td>
<td>39.2</td>
<td>19.4</td>
<td>30</td>
<td>32</td>
<td>39</td>
</tr>
<tr>
<td>T8–T9</td>
<td>133</td>
<td>38.5</td>
<td>18.5</td>
<td>30</td>
<td>33</td>
<td>38</td>
</tr>
<tr>
<td>T9–T10</td>
<td>131</td>
<td>41.7</td>
<td>21.9</td>
<td>30</td>
<td>34</td>
<td>41</td>
</tr>
<tr>
<td>T10–T11</td>
<td>131</td>
<td>41.7</td>
<td>28.3</td>
<td>30</td>
<td>32</td>
<td>40</td>
</tr>
<tr>
<td>T11–T12</td>
<td>123</td>
<td>40.1</td>
<td>22.8</td>
<td>30</td>
<td>33</td>
<td>39</td>
</tr>
<tr>
<td>T0–T12</td>
<td>123</td>
<td>45.1</td>
<td>102.3</td>
<td>385</td>
<td>417</td>
<td>480</td>
</tr>
</tbody>
</table>

Abbreviations: N, number of patients; Q1, first quartile (25%); Q3, third quartile (75%); SD, standard deviation.
(symptom-specific and quality of life questionnaires), the
detection of side effects (drug-specific questionnaires),
the detection of insidious relapses, and of the progress-
ion from RRMS to secondary progressive MS (disability
questionnaire). As we studied RRMS patients with relatively
short disease duration and fairly limited (motor) impair-
ment, our findings cannot be generalized to later stages
of RRMS or progressive MS. The optimal duration of the
monitoring process as well as the frequency and intervals
of self-assessments has to be established per indication. For
early detection of a typical relapse, a predefined schedule of
assessments is not suitable as relapses may occur at any point
in time, and a patient-initiated completion of a questionnaire
seems a better option.

The 75.5% completion adherence in our study is in line
with the existing literature. Bush et al reported a completion
rate of monthly online brief questionnaires during 1 year
for measuring quality of life in patients after hematopoietic
stem cell transplantation of 78.3%.20 In the recent study by
Bhinder et al, most patients complied with intensive online
t-self-assessments, although a substantial minority was unwill-
ing or unable to take part in home assessments.21 These
findings in patients contrast with those in healthy persons. In
young, healthy adults who had received a preventive training
and exercise program, a monthly self-assessment schedule
over a 12-month period had a response rate of only 14% after
1 month, which further decreased to 5% after 12 months.22

The less-than-optimal adherence in our patient group
may relate to various factors. The web-based approach does
not necessarily play a role. In a study of elderly patients with
uncontrolled hypertension who were visited at monthly inter-
vals during a 10-month period for pharmaceutical care, only
69% of the patients completed the study.21 In our study, the
fact that the outcomes were not used for treatment evaluation
by the neurologists may have negatively affected motivation
and adherence. Basch et al reported that without clinician
feedback patients demonstrated limited voluntary interest
in self-reporting between outpatient visits.24 The overall
patient burden of our monthly monitoring schedule was con-
ceivably low, as the interference with daily life was limited
in frequency and time. Yet, the study could have constituted
a mental pressure, as the repeated self-assessments may have
heightened the patients’ awareness of their fatigue or impaired
quality of life and the questions may have confronted them
with the potential negative consequences of their MS. If
the adherence was negatively affected by the (psychologi-
cal) intensity of the monitoring process, one would expect,
however, that patients would become less punctual with
increasing study duration (ie, a worsening interval adher-
ence). Yet, the length of the intervals between consecutive
assessments in the fourth 3-month period (T9 to T12) did
not significantly differ from that in the first 3-month period
(baseline to T3) (data not shown). This rather suggests that
systematic factors have interfered with the interval adher-
ence right from the start. We think that the busy life of many
young people may explain the delay between the receiving of
the email and the completion of the questionnaires, and that
this factor might be more prominent in women, who often
combine work, household activities, and care for children. In
fact, in the study by Bhinder et al, reasons for non-completion
were lack of time or an inability to find time to complete the
questionnaire.21 Our interval data suggest that a way to pre-
vent delays in self-assessments could be to send the emails
3 to 5 days before the assessment is due.

To promote adherence we used short and relevant ques-
tionnaires, sent reminder emails, and provided graphic feed-
back on the changes in personal scores over time.25,26 Other
factors that may improve adherence are the use of smart
phones and short message services.27 It has been known that
in patient care, web-based monitoring should be integrated
into the care process, whereby relations and communication
with health care providers play a critical role.28,29 A study of
diabetes patients found that the frequency of monitoring
blood sugar was increased by more personalized interactions,
notably a higher number of person-centered messages from
the health care provider.29

In MS patient care the start of a disease modifying treat-
ment is followed by monitoring to check whether the response
is as expected and the therapeutic goal is being met. Given the
predictive value of a short-term clinical worsening after the
start of treatment with respect to long-term disability, moni-
toring of clinical features can provide a signal for a switch
to a more potent drug or provide motivation to adhere to the
existing treatment.30 In daily practice, the monitoring pro-
cess coincides with outpatient visits, during which patients
are assessed clinically and by magnetic resonance imaging.
Intensive online monitoring using PROs provides unique and
complementary data, as these instruments comprehensively
measure the benefits and adverse effects of a treatment on
both the physical, emotional, and social health status.7
A recent study in amyotrophic lateral sclerosis patients
showed that the online use of the Amyotrophic Lateral
Sclerosis Functional Rating Scale compared well to the in-
iclinic evaluation and complements the onsite assessments.31
Intensive online monitoring in MS using PROs might also
help to quantify the effect of symptomatic treatments for
walking disability, fatigue, depression, anxiety, or bladder
dysfunction, whereas the Multiple Sclerosis Impact Profile,
a self-report tool that measures the objectified and perceived
impact of MS, might complement the EDSS. 32

In this study, we assessed in RRMS patients the adher-
ence to a monthly online self-assessment schedule for
intensive monitoring aspects of their disease by using short
questionnaires. As the scores were not made available to the
neurologists or MS-nurses, our data do not inform on the
clinical relevance of this approach. Future studies are needed
to investigate PRO findings in correlation with objective
measures like EDSS and magnetic resonance imaging, the
reliability of the various PROs, what constitutes a clinically
relevant change, and the optimal frequency of assessments.

In all, our data suggest that intensive web-based moni-
toring in RRMS patients is feasible for research purposes
in terms of adherence. However, measures need to be taken
to improve the timely completion of questionnaires, like
sending the emails 3 to 5 days before the assessment is due,
enabling the use of smartphones for completion, and integra-
ting the online assessments into the care process.

Acknowledgments
The authors thank Esther van Noort and Anton Kool, Curavista
bv, Geertruidenberg, The Netherlands, for developing the
study website and for fruitful discussions. We are grateful
to Thomas Harrison for critically reading the manuscript.
The OPTIVIT study group is comprised of the following:
neurologists: Dr Perquin, Medisch Centrum Haaglanden,
Den Haag; Dr Baart, Dr Tacke, Streekziekenhuis Midden
Twente, Hengelo; Dr Pasmans, Atrium Medisch Centrum,
Kerkrade; Dr Koppenaal, Zaan Medisch Centrum, Zaanland;
Dr Hageman, Medisch Centrum Twente, Enschede; Dr Groen,
Dr strikwerda, Dr Vanderstok, ’t Lange Land Ziekenhuis,
Zoetermeer; Dr Hoitsma, Diakonessen Ziekenhuis, Leiden;
Dr Jongen, Dr Tjon Eng Soe, Dr Zwanikken, Multiple Sclerose
Centrum Nijmegen, Nijmegen; Dr Dijkstra, Dr Lenssen,
Elkerliek Ziekenhuis, Helmond; Dr Zorgdrager, Sint Lucas
Ziekenhuis, Winschoten; Dr ter Bruggen, Dr Louwerse, Dr van
Zagten, Dr Visse, Jeroen Bosch Ziekenhuis, Den Bosch; Dr
Heerema, Dr Klaver-Schaar, IJsselland Ziekenhuis, Capelle
aan de IJssel; Dr Baal, Ziekenhuis Rivierenland, Tiel; Dr Gauw,
Dr Oonk, Waterland Ziekenhuis, Purmerend; Dr Keuneen, Dr
van Woerkom, Dr van de Zwart, HAGA Ziekenhuis, Den
Haag; Dr Driesen, Dr Verhey, Dr van Oudenaarden, Vlietland
Ziekenhuis, Schiedam; Dr Oosterhoff, Dr ten Have, Meander
Medisch Centrum, Baarn; Dr Mispelblom Beyer, Spaarne
Ziekenhuis, Hoofddorp; Dr Scholtes, Gemini Ziekenhuis, Den
Helder; Dr Schiphof, Ziekenhuis Bernhoven, Veghel; Dr van
der Heijden, Dr Pop, Viecui Medisch Centrum; Venlo-Venray;
Dr Sanders, Amphia Ziekenhuis, Breda; Dr Jansen, Antonius
Ziekenhuis, Sneek; Dr Willems, Centraal Militair Hospitaal,
Utrecht; Dr Visser, St Elisabeth Ziekenhuis, Tilburg; Dr Jonker,
Dr de Keijzer, Isala Klinieken, Zwolle; Dr Jansen, Dr Vlam,
TweeSteden Ziekenhuis, Tilburg; Dr van der Meulen, Mesos
Medisch Centrum, Utrecht; Dr Siegers, St Antoniuziekenhuis,
Utrecht; Dr Tans – de Jongh, Bronovo Ziekenhuis, Den Haag;
Dr Koeman, Admiraal de Ruyter Ziekenhuis, Vlissingen;
Dr Jansen, Ziekenhuis Gelderse Vallei, Ede; Dr Hiel, Dr
Valkenburg, Maxima Medisch Centrum, Veldhoven; Dr
Lanting, Ziekenhuis Amstelveen, Amstelveen; Dr Skallebaek,
Gelre Ziekenhuis, Apeldoorn. Nurses: Mrs Boringa, Antonius
Ziekenhuis, Sneek; Mrs Slaats, Mrs van Mill, Jeroen Bosch
Ziekenhuis, Den Bosch; Mrs Booy, Amphia Ziekenhuis,
Breda; Mrs Westdorp, Laurentius Ziekenhuis, Roermond;
Mrs Bergmans, Viercui Medisch Centrum, Venlo-Venray;
Mrs Kempkens, Maasland Ziekenhuis, Sittard; Mr Heerings,
Universitair Medisch Centrum Groningen; and Mrs de Jong,
Hofpoort Ziekenhuis, Woerden.

Disclosure
The study was funded by Sanofi-Aventis, Gouda and TEVA
Pharma, Haarlem, The Netherlands, and designed in collabora-
tion with Esther van Noort, Curavista bv, Geertruidenberg, The
Netherlands Marianka van der Tol, TEVA Pharma, Haarlem,
and George Peters, Sanofi-Aventis, Gouda, The Netherlands.
Dr Jongen has received honoraria from Allergan, Eindhoven;
Almirall, Utrecht; Biogen-Idec, Badhoevedorp; Merck-Serono,
Schiphol-Rijk; Novartis, Arnhem; Sanofi-Aventis, Gouda, The
Netherlands, and TEVA for contributions to symposia as a
speaker and for consultancy activities. The MS4 Research
Institute has received funding from Bayer-Schering, Midjrecht,
The Netherlands Merck-Serono, Sanofi-Aventis, and TEVA for
investigator-initiated research projects. The authors report no
other conflicts of interest in this work.

References
A randomized, placebo-controlled trial of natalizumab for relapsing
A placebo-controlled trial of oral fingolimod in relapsing multiple
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Investigators. Sustained-release oral fampridine in multiple sclerosis: a ran-


